Nobelpharma builds commercial ops with Japan fosphenytoin launch
This article was originally published in Scrip
Executive Summary
Nobelpharma, a specialist Japanese venture, is continuing to expand its commercial portfolio with the launch in its home market of the anticonvulsant Fostoin (fosphenytoin sodium hydrate), in a move that also marks another small step forward to closing Japan's "drug lag".